AstraZeneca Claims Study Confirms 100% protection against Severe Disease, Hospitalization and Death in the Primary Analysis of Phase III Trials

Alfredo Cuadros



Pharmaceutical AstraZeneca releasing new details in its ongoing COVID-19 vaccine phase 3 trials.

The company is claiming to have confirmed 100 percent protection against COVID related severe disease, hospitalization, and death based on primarily analysis.

The company bases the statement from phase 3 trials in the United Kingdom, Brazil and South Africa after reporting no severe cases and no hospitalizations for more than 22 days after the first dose.

The early results were based on trials of over 17 thousand participants.

A chief investigator of the oxford vaccine trial says the new data may be important verification to help get the AstraZeneca vaccine  obtain emergency use authorization around the world.

Leave a Reply

Your email address will not be published.